Literature DB >> 16816235

Association of initial antipsychotic response to clozapine and long-term weight gain.

Ya Mei Bai1, Chao-Cheng Lin, Jen-Yeu Chen, Chih-Yuan Lin, Tung-Ping Su, Pesus Chou.   

Abstract

OBJECTIVE: The aim of this study was to test whether the initial antipsychotic response to clozapine is related to subsequent weight change.
METHOD: This study was an 8-year retrospective chart review of 96 hospitalized patients with schizophrenia. Data on monthly weight change, initial clinical response, age, gender, clozapine dose, and concomitant use of mood stabilizers and other antipsychotics were analyzed.
RESULTS: Fifty-five (57.3%) of the patients received clozapine over the entire 8-year period; these subjects experienced an average weight gain of 11.7 kg (SD=1.6). Seventeen of these patients (30.9%) who had a significant initial clinical response (CGI improvement rating of 1 or 2 during the first 14 months) gained significantly more weight (13.8 kg [SD=8.4]) than did the 38 patients without a significant initial response (4.5 kg [SD=12.0]). Multiple linear regression analysis showed significant initial clinical response and lower baseline body mass index were associated with significantly more weight gain.
CONCLUSIONS: The results show that initial antipsychotic response to clozapine is associated with subsequent long-term weight gain as measured over 8 years.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816235     DOI: 10.1176/ajp.2006.163.7.1276

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   19.242


  14 in total

1.  Dramatic weight loss associated with commencing clozapine.

Authors:  John Lally; Colm McDonald
Journal:  BMJ Case Rep       Date:  2011-11-08

2.  Of rats and schizophrenia.

Authors:  Patricia Boksa
Journal:  J Psychiatry Neurosci       Date:  2007-01       Impact factor: 6.186

3.  Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.

Authors:  David E Kemp; Christoph U Correll; Mauricio Tohen; Melissa P Delbello; Stephen J Ganocy; Robert L Findling; Kiki Chang
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-10-10       Impact factor: 2.576

Review 4.  Factors associated with response to clozapine in schizophrenia: a review.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Haruo Kashima
Journal:  Psychopharmacol Bull       Date:  2011

5.  Clinical phenotype of bipolar disorder with comorbid binge eating disorder.

Authors:  Susan L McElroy; Scott Crow; Joanna M Biernacka; Stacey Winham; Jennifer Geske; Alfredo B Cuellar Barboza; Miguel L Prieto; Mohit Chauhan; Lisa R Seymour; Nicole Mori; Mark A Frye
Journal:  J Affect Disord       Date:  2013-06-03       Impact factor: 4.839

6.  Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.

Authors:  Timothy L Ramsey; Mark D Brennan
Journal:  Schizophr Res       Date:  2014-10-18       Impact factor: 4.939

7.  The association between weight change and symptom reduction in the CATIE schizophrenia trial.

Authors:  Eric Hermes; Henry Nasrallah; Vicki Davis; Jonathan Meyer; Joseph McEvoy; Donald Goff; Sonia Davis; T Scott Stroup; Marvin Swartz; Jeffrey Lieberman; Robert Rosenheck
Journal:  Schizophr Res       Date:  2011-02-21       Impact factor: 4.939

Review 8.  Pharmacological management of atypical antipsychotic-induced weight gain.

Authors:  Trino Baptista; Yamily ElFakih; Euderruh Uzcátegui; Ignacio Sandia; Eduardo Tálamo; Enma Araujo de Baptista; Serge Beaulieu
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 9.  Obesity in Adolescents with Psychiatric Disorders.

Authors:  Ariana M Chao; Thomas A Wadden; Robert I Berkowitz
Journal:  Curr Psychiatry Rep       Date:  2019-01-19       Impact factor: 5.285

10.  Relationships between Brain Structure and Metabolic Changes in Schizophrenia Patients Treated with Olanzapine: A Voxel-Based Morphometric Study.

Authors:  Genevieve Letourneau; Lahcen Ait Bentaleb; Benjamin Stip; David Luck; Emmanuel Stip
Journal:  Schizophr Res Treatment       Date:  2011-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.